Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection

被引：2
作者：
Mohit Mittal
Ke-Qin Hu
机构：
[1] Division of Gastroenterology and Hepatology, School of Medicine, University of California Irvine, Orange, 92868, CA
来源：
Current Hepatology Reports | 2017年 / 16卷 / 2期
关键词：
Chronic liver disease; Hepatitis B virus (HBV); Hepatocellular carcinoma; Occult hepatitis B virus infection (OBI); Reactivation of hepatitis B;
D O I：
10.1007/s11901-017-0339-9
中图分类号：
学科分类号：
摘要：
Purpose of Review: The purpose of this review is to discuss the clinical implications of occult hepatitis B virus infection (OBI) and management options. Recent Findings: Data regarding the role of OBI as a co-infection and its ability to facility progression of cirrhosis and hepatocellular carcinoma remain conflicting. In a recent meta-analysis, those with chronic hepatitis C and occult hepatitis B co-infection were found to be at increased risk for development of hepatocellular carcinoma. There remains limited data on how to manage these patients to prevent disease progression. Summary: OBI refers to the presence of hepatitis B viral (HBV) DNA in serum or hepatocytes in the absence of detectable HBV surface antigen (HBsAg) with or without serological markers of previous exposure. As our understanding of the virology has progressed, so has our understanding of the clinical implications of OBI. Despite the growing evidence of the clinical implications of OBI, there are also several conflicting reports in the literature. After years of research, we have further understanding of the pathogenesis of OBI, but many questions remain unanswered. What we do know is that what was once felt to be a relatively innocuous entity is now regarded as a clinically very relevant disease process requiring appropriate assessment and individualized clinical management. © Springer Science+Business Media New York 2017.
引用
收藏
页码：90 / 96
页数：6
相关论文
共 95 条
  • [1] Ott J.J., Stevens G.A., Groeger J., Wiersma S.T., Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, 30, pp. 2212-2219, (2012)
  • [2] Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, Lancet, 386, pp. 1546-1555, (2015)
  • [3] Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., Et al., Statements from the Taormina expert meeting on occult hepatitis B virus infection, J Hepatol, 49, pp. 652-657, (2008)
  • [4] Mason A.L., Xu L., Guo L., Kuhns M., Perrillo R.P., Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen, Hepatology, 27, pp. 1736-1742, (1998)
  • [5] Gerlich W.H., Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy, Intervirology, 57, pp. 202-211, (2014)
  • [6] Stramer S.L., Notari E.P., Krysztof D.E., Dodd R.Y., Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?, Transfusion, 53, pp. 2449-2458, (2013)
  • [7] Allain J.P., Mihaljevic I., Gonzalez-Fraile M.I., Gubbe K., Holm-Harritshoj L., Garcia J.M., Et al., Infectivity of blood products from donors with occult hepatitis B virus infection, Transfusion, 53, pp. 1405-1415, (2013)
  • [8] Coppola N., Loquercio G., Tonziello G., Azzaro R., Pisaturo M., HBV transmission from an occult carrier with five mutations the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient, J Clin Virol, 58, pp. 315-317, (2013)
  • [9] Furuta R.A., Kondo Y., Saito T., Tomita M., Oka K., Kishimoto Y., Transfusions of red blood cells from an occult hepatitis B virus carrier without apparent signs of transfusion-transmitted hepatitis B infection, Transfus Med, 18, pp. 379-381, (2008)
  • [10] Su T.H., Chen P.J., Chen T.C., Cheng H.R., Li L., Lin K.S., Et al., The clinical significance of occult hepatitis B transfusion in Taiwan—a look-back study, Transfus Med, 21, pp. 33-41, (2011)
12345678910